Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Vericel to Report Second-Quarter 2021 Financial Results on August 4, 2021 | ||||||||||||||||
By: GlobeNewswire - 21 Jul 2021 | Back to overview list |
|||||||||||||||
CAMBRIDGE, Mass., July 21, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its second-quarter 2021 financial results and business highlights.
To participate in the live call by telephone, please call (877) 312-5881 and reference Vericel Corporation second-quarter 2021 earnings call. If calling from outside the U.S., please use the international phone number (253) 237-1173. If you are unable to participate in the live call, the webcast will be available at http://investors.vcel.com/events-presentations until August, 2022. A replay of the call will also be available until 11:30am (EDT) on August 11, 2021 by calling (855) 859-2056, or from outside the U.S. (404) 537-3406. The conference ID is 5824035. About Vericel Corporation Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American commercial rights to NexoBrid®, a registration-stage biological orphan product for debridement of severe thermal burns. For more information, please visit the company’s website at www.vcel.com. Epicel® and MACI® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2021 Vericel Corporation. All rights reserved. Investor Contacts: |
||||||||||||||||
|
||||||||||||||||
Copyright 2021 GlobeNewswire | Back to overview list |